Source: Annual Congress 2009 - Towards improving asthma control
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. D. C. Vennera, R. Mora, A. Valero, J. Bartra, R. Muñoz, C. Picado (Barcelona, Spain). Omalizumab in severe uncontrolled asthma: two and a half year clinical experience. Eur Respir J 2009; 34: Suppl. 53, 275

Member's Comments

No comment yet.

Related content which might interest you: 10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Source: Eur Respir J 2013; 42: 1224-1233 Year: 2013 Omalizumab in children with severe asthma (SA): Which parameters improve after a 16 week trial? Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 One year following a real life experience of omalizumab for moderate to severe persistent allergic asthma in Malta Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Omalizumab in severe asthma: real life study Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Reslizumab for uncontrolled eosinophilic asthma in patients who experienced a single exacerbation in the previous year: sub-analysis of two phase 3 trials Source: International Congress 2017 – Asthma management Year: 2017 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Efficacy of Omalizumab in adult and pediatric severe allergic asthma according to presence of multiple allergic comorbidities: evidence from the STELLAIR study. Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Omalizumab in severe allergic asthma: a 4-year real world experience, Fife, Scotland Source: International Congress 2017 – Asthma management Year: 2017